Stop Smoking Treatments Prescribed by UK Doctors

Tobacco smoking remains the leading preventable cause of death in the UK, responsible for approximately 78,000 deaths annually and 480,000 hospital admissions.

It causes 72% of lung cancers, 80% of COPD cases, and doubles cardiovascular disease risk. The economic burden exceeds £12.6 billion per year in healthcare costs, lost productivity, and social care.

Health recovery timeline after quitting demonstrates rapid physiological benefit:

• 20 minutes: heart rate and blood pressure begin normalising
• 48 hours: carbon monoxide clears; taste and smell start recovering
• 72 hours: bronchial tubes relax; breathing capacity improves
• 2-12 weeks: circulation improves; lung function increases by up to 10%
• 1 year: coronary heart disease risk drops to half that of a continuing smoker
• 5 years: stroke risk falls to that of a non-smoker
• 10 years: lung cancer risk falls to approximately half that of a continuing smoker
• 15 years: coronary heart disease risk matches that of a lifelong non-smoker

Nicotine dependence is a chronic relapsing condition driven by the pharmacology of nicotine binding to alpha-4-beta-2 nicotinic acetylcholine receptors in the mesolimbic dopamine pathway.

Each cigarette delivers nicotine to the brain within 10-20 seconds, producing a rapid dopamine surge that reinforces the behaviour.

Tolerance develops within days, requiring escalating doses to achieve the same effect.

The Fagerstrom Test for Nicotine Dependence quantifies severity:

• Time to first cigarette after waking (under 5 minutes = high dependence)
• Number of cigarettes per day (20+ = high dependence)
• Difficulty refraining in restricted places
• Smoking more in the morning than the rest of the day

Highly dependent smokers (Fagerstrom score 7-10) benefit most from pharmacotherapy and should be prioritised for prescription support.

NICE PH10 is clear: every smoker attempting to quit should be offered pharmacological assistance.

Three first-line pharmacotherapies are recommended by NICE PH10 for smoking cessation.

Selection depends on patient preference, nicotine dependence level, contraindications, and prior quit attempt history.

Varenicline (Champix) is a partial agonist at the alpha-4-beta-2 nicotinic receptor.

It produces approximately 45% of the dopamine release that nicotine generates, reducing cravings and withdrawal, while simultaneously blocking nicotine from binding if the patient smokes.

• Days 1-3: 0.5 mg once daily
• Days 4-7: 0.5 mg twice daily
• Day 8 onwards (quit date): 1 mg twice daily for 11 weeks (12-week total course)

Efficacy data: the EAGLES trial (8,144 participants) demonstrated 12-week continuous abstinence rates of 21.8% (varenicline) vs 17.7% (NRT) vs 15.7% (bupropion) vs 9.4% (placebo).

Extending to 24 weeks of treatment improves long-term rates further. Varenicline was temporarily withdrawn in 2021 due to N-nitrosamine contamination but has returned to the UK market.

Nicotine replacement therapy (NRT) delivers nicotine without the 7,000+ harmful chemicals in tobacco smoke. Available forms include:

• Patches (16-hour or 24-hour): provide steady-state nicotine levels; step-down over 8-12 weeks
• Inhalator, nasal spray, mouth spray, lozenges, gum: provide rapid-onset nicotine for acute cravings

Combination NRT (patch plus a short-acting product) is more effective than any single NRT form and approaches varenicline efficacy. NICE recommends combination NRT as a first-line option.

Bupropion (Zyban) is a noradrenaline-dopamine reuptake inhibitor that reduces withdrawal symptoms and cravings. Dose: 150 mg daily for 6 days, then 150 mg twice daily for 7-9 weeks.

Seizure risk is 1 in 1,000 at recommended doses — contraindicated in patients with epilepsy, eating disorders, or concurrent MAOIs.

Prescribing protocol at Dr. Presc:

• Set a quit date 1-2 weeks after starting varenicline or bupropion
• Start NRT on the quit date itself
• Combine pharmacotherapy with behavioural support (even brief advice increases quit rates by 1-3%)
• Review at 2 weeks, 4 weeks, and 12 weeks post-quit date
• Consider extending treatment to 24 weeks for highly dependent smokers or those who relapse after initial success

Nicotine withdrawal symptoms peak within the first 72 hours of cessation and gradually subside over 2-4 weeks.

Understanding the timeline and having strategies prepared significantly improves quit success.

Withdrawal symptom timeline:

• Hours 4-24: irritability, anxiety, difficulty concentrating, restlessness
• Days 1-3: peak withdrawal — intense cravings (lasting 3-5 minutes each), insomnia, increased appetite, depressed mood
• Weeks 1-4: gradual improvement; cravings become less frequent and intense; appetite increase may persist
• Months 1-3: psychological cravings triggered by situational cues (after meals, with coffee, socialising)

Relapse patterns: Data from the Smoking Toolkit Study shows that 75% of unaided quit attempts fail within the first week.

With pharmacotherapy, this drops to 40-50% at one week and 65-70% at one year. Most relapse is triggered by situational cues rather than physiological withdrawal.

Evidence-based relapse prevention strategies:

• Identify personal high-risk situations (pub, work breaks, stressful events) and develop specific coping plans
• Use short-acting NRT (mouth spray, inhalator) for acute cravings — the craving will pass within 3-5 minutes whether or not you smoke
• Change routines associated with smoking: alter the post-meal ritual, take a different route past the shop
• Delay technique: when a craving hits, wait 10 minutes and engage in a distracting activity

Weight management during quitting: Average weight gain after quitting is 4-5 kg over 12 months, driven by increased appetite and reduced metabolic rate (nicotine increases resting metabolism by 7-15%).

• Increase physical activity — walking 30 minutes daily offsets much of the metabolic change
• Stock healthy snacks (vegetable sticks, sugar-free gum) for oral substitution
• Do not attempt a restrictive diet simultaneously — this doubles the stress and increases relapse risk
• Varenicline and NRT partially attenuate weight gain during use

Mental health considerations: Smokers have 2-3 times the prevalence of depression and anxiety compared with non-smokers.

Contrary to patient belief, quitting smoking improves mental health outcomes.

A meta-analysis in the BMJ showed that cessation reduces anxiety, depression, and stress while improving positive mood and quality of life, with effect sizes comparable to antidepressant medication.

Long-term success depends on embedding new habits and addressing the psychological and social dimensions of smoking that persist after nicotine dependence resolves.

Behavioural support significantly amplifies pharmacotherapy. NICE PH10 recommends combining medication with either group-based or individual counselling.

NHS Stop Smoking Services provide free specialist support and achieve 4-week quit rates of 35-50%.

The combination of medication plus behavioural support is the most cost-effective health intervention in the NHS.

Practical elements of behavioural support:

• Motivational interviewing to strengthen personal reasons for quitting
• Cognitive restructuring of beliefs about smoking ("I need a cigarette to relax" vs "nicotine withdrawal creates the anxiety I am trying to relieve")
• Developing a relapse prevention plan with specific trigger-response pairings
• Regular check-ins during the critical first 12 weeks

Financial motivation: A 20-per-day smoker at average UK prices spends approximately £5,000 per year.

Calculating cumulative savings and directing funds towards a tangible goal (holiday, home improvement) provides ongoing motivational reinforcement.

Social environment management:

• Communicate your quit date to friends, family, and colleagues — social accountability improves success
• If your partner smokes, quitting together doubles individual success rates
• Avoid heavy alcohol consumption in the first 4 weeks — alcohol is the single strongest trigger for relapse in social smokers
• Clean the car, wash curtains, and deep-clean living spaces to eliminate lingering smoke cues

E-cigarettes and vaping: NICE NG209 acknowledges that vaping is substantially less harmful than smoking and can aid cessation.

The MHRA is developing a regulatory pathway for medicinally licensed e-cigarettes. Current evidence from the Cochrane Review (2022) shows e-cigarettes are more effective than NRT for cessation (RR 1.

63). However, long-term safety data remain limited, and the recommendation is to use vaping as a stepping stone to complete nicotine abstinence rather than a permanent substitute.

Carbon monoxide (CO) monitoring: Exhaled CO drops below 10 ppm within 48 hours of cessation and provides objective validation of quit status.

CO verification at follow-up appointments reinforces motivation and can detect unreported smoking.